Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Key difference between this and kanabo.
kanabo didn't ipo to retail investors, so the big boys bought and then the public bought in on float.
Cbx ipo predominantly to retail investors, who have all sold and will do while there still up.
The big boys don't want to know because of this and it will keep dropping
There's nothing decent that cbx offers current so you won't see many big players join this
Sorry
This part looks at the overall strategy. Neither company generates any sales so there is no history of operating performance nor financial data to compare. Further, neither company has articulated a detailed business development strategy.
CBX
CBX plans to build a brand to sell cannabinoids that are derived from biosynthesis and, in the the longer-term, aspires to develop a “grown” cannabis business. The target market is the wellness sector: initial products will be topical (creams) focused on skin care (Q3 2021) and movement (company’s presentation on Primary Bid states Q1 2021 but I strongly suspect this should read Q1 2022 – CHECK).
The emphasis of CBX is very much on product development, marketing and brand development and differentiation rather than building its own production operations.
Kanabo
Kanabo states in its prospectus that “the core strategic goal of the Enlarged Group is to increase the sale of its Retail CBD Products within the Primary Markets.” The primary markets are UK and Germany.
In the long run, Kanabo also aims to "to pair a registered medical device with its Unlicensed Medical Cannabis Oils." To further this part of the strategy, Kanabo has outsourced to a third-party the obtaining of a CE mark for its trademarked VapePod Medical device, which it hope to secure in the first half of 2021.
Kanabo makes it clear that it is some way from delivering the medical part of its strategy for which it needs to be a pioneer amid a very complex and still emerging legal, regulatory and medical landscape, which may be many years from being settled or established.
Key observations:
Both companies are some way from selling products and generating any significant revenues. CBX's focus on topical products based on synthetic, zero-THC CBD may mean it has fewer regulatory and legal hurdles to overcome to start generating sales. However, it could be argued that KNB's longer term focus on developing and selling medicinal CBD products offers investors the greater long-term potential and a chance to escape what may quickly become a crowded consumer market.
Both companies will lean heavily on key partnerships and relationships to develop, manufacture and sell products.
CBX will develop and brand its CBD products but they will be manufactured abroad by suppliers that the group has identified including Purisys LLC, Lygos Inc, Willow Biosciences Inc. and Demetrix, Inc. and Arcania Apothecary Limited (its Somerset, United Kingdom based contract manufacturer which is responsible for production and packaging the Company’s products).
Similarly, Kanabo relies heavily on its relationship with Jupiter Technology, which owns the IPR to the VapePod and manufactures the devices. Kanabo has applied for a patent "in respect of its Medical Cannabis Oil, Nabinnol,
and its diluent formulation. As at the date of this document, Kanabo has no registered patents". CBX also has no current IPR or patents.
Best
Happy